{"id":19725,"date":"2022-01-05T15:32:12","date_gmt":"2022-01-05T14:32:12","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=19725"},"modified":"2022-01-05T15:32:15","modified_gmt":"2022-01-05T14:32:15","slug":"le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/","title":{"rendered":"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance"},"content":{"rendered":"\n

Article paru sur le site de Zonebourse.com<\/a> le 03 janvier 2022<\/p>\n\n\n\n

Le projet a \u00e9t\u00e9 d\u00e9sign\u00e9 laur\u00e9at de l\u2019Appel \u00e0 Manifestation d\u2019Int\u00e9r\u00eat \u00ab Maladies infectieuses \u00e9mergentes et nouvelles menaces radiologiques, biologiques et chimiques \u00bb<\/p>\n\n\n\n

Pherecydes Pharma<\/a><\/strong>, soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans la phagoth\u00e9rapie de pr\u00e9cision destin\u00e9e \u00e0 traiter les infections bact\u00e9riennes r\u00e9sistantes aux antibiotiques et\/ou compliqu\u00e9es, et le CEA, annoncent aujourd\u2019hui la s\u00e9lection du projet PhagECOLI soumis dans le cadre de l\u2019Appel \u00e0 Manifestation d\u2019Int\u00e9r\u00eat – Maladies Infectieuses Emergentes et Nouvelles Menaces Radiologiques Biologiques et Chimiques. Ce projet recevra une subvention de Bpifrance de 2 M\u20ac, soit 50% de son co\u00fbt estim\u00e9, qui se r\u00e9partiront de la fa\u00e7on suivante : 80% pour Pherecydes Pharma et 20% pour le CEA.<\/p>\n\n\n\n

Le projet PhagECOLI s\u2019appuie sur les expertises et exp\u00e9riences compl\u00e9mentaires de Pherecydes Pharma et du CEA. Ce projet d\u2019une dur\u00e9e de trois ans a pour objectif de proposer de nouveaux traitements des infections \u00e0\u00a0E. Coli<\/em>\u00a0difficiles \u00e0 traiter ou r\u00e9sistantes, gr\u00e2ce \u00e0 la phagoth\u00e9rapie de pr\u00e9cision. <\/p>\n\n\n\n

Afin de r\u00e9pondre au mieux au besoin th\u00e9rapeutique, Pherecydes Pharma et le CEA d\u00e9velopperont une nouvelle g\u00e9n\u00e9ration d\u2019outils de mesure de l\u2019efficacit\u00e9 des phages anti-E. Coli<\/em>\u00a0sur la souche bact\u00e9rienne du patient. Ces nouveaux outils pourront ensuite \u00eatre la base d\u2019une toute nouvelle g\u00e9n\u00e9ration de phagogrammes1<\/sup>\u00a0pour les diff\u00e9rentes bact\u00e9ries cibles. Ce soutien financier permettra \u00e9galement \u00e0 Pherecydes Pharma d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement de ses phages anti-E. coli<\/em>.<\/p>\n\n\n\n

L\u2019Organisation Mondiale de la Sant\u00e9 (OMS) a class\u00e9 Escherichia coli<\/em> dans le groupe des bact\u00e9ries pr\u00e9sentant une priorit\u00e9 critique en termes de recherche de nouveaux traitements, du fait de sa dangerosit\u00e9 et de sa r\u00e9sistance aux antibiotiques. Selon les donn\u00e9es du Centre europ\u00e9en de pr\u00e9vention et de contr\u00f4le des maladies (ECDC), les infections \u00e0 E. coli<\/em> r\u00e9sistantes repr\u00e9sentent les infections les plus fr\u00e9quentes en Europe en milieu hospitalier avec plus de 163 000 cas par an.<\/p>\n\n\n\n

Guy-Charles Fanneau de La Horie, Pr\u00e9sident du Directoire de Pherecydes Pharma<\/strong>, d\u00e9clare : \u00ab Je suis ravi de pouvoir conjuguer nos efforts avec ceux entrepris par le CEA depuis quelques ann\u00e9es dans le domaine de la d\u00e9tection de l\u2019activit\u00e9 des phages sur une bact\u00e9rie cible. L\u2019approche cod\u00e9velopp\u00e9e avec le CEA a pour but de mettre en place une toute nouvelle g\u00e9n\u00e9ration d\u2019outils fiables, rapides et sensibles permettant un traitement optimis\u00e9 pour les patients et les praticiens. Nous sommes \u00e9galement tr\u00e8s fiers de recevoir le soutien de Bpifrance pour ce projet avec nos phages anti-<\/em>E. Coli. \u00bb<\/em><\/p>\n\n\n\n

Nad\u00e8ge Nief, Directrice adjointe du d\u00e9partement des microtechnologies pour la sant\u00e9 au CEA,<\/strong>d\u00e9clare : \u00ab Nous sommes tr\u00e8s heureux de pouvoir d\u00e9velopper cette nouvelle g\u00e9n\u00e9ration d\u2019outils avec Pherecydes Pharma. Par son exp\u00e9rience et ses projets, Pherecydes est aujourd\u2019hui l\u2019acteur industriel europ\u00e9en le plus avanc\u00e9 dans le domaine et son approche de phagoth\u00e9rapie de pr\u00e9cision correspond totalement aux recherches men\u00e9es par le CEA sur le phagogramme optique depuis quelques ann\u00e9es. Nous sommes convaincus qu\u2019ensemble nous pourrons mettre au point de nouveaux outils rapides et industrialisables pour un traitement efficace des patients en impasse th\u00e9rapeutique. \u00bb<\/em><\/p>\n\n\n\n

A propos de Pherecydes Pharma<\/strong><\/p>\n\n\n\n

Cr\u00e9\u00e9e en 2006, Pherecydes Pharma est une soci\u00e9t\u00e9 de biotechnologie qui d\u00e9veloppe des traitements contre les infections bact\u00e9riennes r\u00e9sistantes, responsables de nombreuses infections graves. La soci\u00e9t\u00e9 a mis au point une approche innovante, la phagoth\u00e9rapie de pr\u00e9cision, bas\u00e9e sur l\u2019utilisation de phages, virus naturels tueurs de bact\u00e9ries.<\/p>\n\n\n\n

Pherecydes Pharma d\u00e9veloppe un portefeuille de phages ciblant 3 bact\u00e9ries parmi les plus r\u00e9sistantes et dangereuses qui repr\u00e9sentent \u00e0 elles seules plus de deux tiers des infections nosocomiales r\u00e9sistantes :\u00a0Staphylococcus aureus<\/em>,\u00a0Escherichia coli\u00a0<\/em>et\u00a0Pseudomonas aeruginosa<\/em>. <\/p>\n\n\n\n

Le concept de phagoth\u00e9rapie de pr\u00e9cision a \u00e9t\u00e9 appliqu\u00e9 avec succ\u00e8s chez plusieurs dizaines de patients dans le cadre de traitements compassionnels, sous la supervision de l\u2019Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM). Pherecydes Pharma, dont le si\u00e8ge social est \u00e0 Nantes, s’appuie sur une \u00e9quipe d\u2019une vingtaine d\u2019experts issus de l’industrie pharmaceutique, des biotechnologies et de la recherche acad\u00e9mique.<\/p>\n\n\n\n

Pour plus d\u2019informations,\u00a0www.pherecydes-pharma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Article paru sur le site de Zonebourse.com le 03 janvier 2022 Le projet a \u00e9t\u00e9 d\u00e9sign\u00e9 laur\u00e9at de l\u2019Appel \u00e0 Manifestation d\u2019Int\u00e9r\u00eat \u00ab Maladies infectieuses \u00e9mergentes et nouvelles menaces radiologiques, biologiques et chimiques \u00bb Pherecydes Pharma, soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans la phagoth\u00e9rapie de pr\u00e9cision destin\u00e9e \u00e0 traiter les infections bact\u00e9riennes r\u00e9sistantes aux antibiotiques et\/ou […]<\/p>\n","protected":false},"author":139,"featured_media":19727,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"\nLe projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-05T14:32:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-05T14:32:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"570\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance\",\"datePublished\":\"2022-01-05T14:32:12+00:00\",\"dateModified\":\"2022-01-05T14:32:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\"},\"wordCount\":769,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\",\"name\":\"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg\",\"datePublished\":\"2022-01-05T14:32:12+00:00\",\"dateModified\":\"2022-01-05T14:32:15+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg\",\"width\":800,\"height\":570,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/","og_locale":"en_GB","og_type":"article","og_title":"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-01-05T14:32:12+00:00","article_modified_time":"2022-01-05T14:32:15+00:00","og_image":[{"width":800,"height":570,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance","datePublished":"2022-01-05T14:32:12+00:00","dateModified":"2022-01-05T14:32:15+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/"},"wordCount":769,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/","name":"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg","datePublished":"2022-01-05T14:32:12+00:00","dateModified":"2022-01-05T14:32:15+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/01\/Arrosage-argent.jpg","width":800,"height":570,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/le-projet-phagecoli-de-pherecydes-pharma-et-du-cea-recoit-une-subvention-de-2-me-de-bpifrance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"Le projet PhagECOLI de Pherecydes Pharma et du CEA re\u00e7oit une subvention de 2 M\u20ac de Bpifrance"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-14 17:38:46","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19725"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=19725"}],"version-history":[{"count":10,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19725\/revisions"}],"predecessor-version":[{"id":19749,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19725\/revisions\/19749"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/19727"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=19725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=19725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=19725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}